Last reviewed · How we verify
CAT-8015 immunotoxin — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
CAT-8015 immunotoxin (CAT-8015 immunotoxin) — Cambridge Antibody Technology.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CAT-8015 immunotoxin TARGET | CAT-8015 immunotoxin | Cambridge Antibody Technology | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CAT-8015 immunotoxin CI watch — RSS
- CAT-8015 immunotoxin CI watch — Atom
- CAT-8015 immunotoxin CI watch — JSON
- CAT-8015 immunotoxin alone — RSS
Cite this brief
Drug Landscape (2026). CAT-8015 immunotoxin — Competitive Intelligence Brief. https://druglandscape.com/ci/cat-8015-immunotoxin. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing